SSS Sunvest Minerals Corp

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(OTCQX:SCTPF), a biopharmaceutical
company developing cancer stem cell-related therapeutics, today provided the
following corporate update:




--  Safety and pharmacokinetic data from studies in rodents and non-human
    primates, using several variants of the company's high-affinity CD47
    antagonist, are expected to become available in the third quarter. Stem
    Cell Therapeutics (SCT) has chosen to target the CD47 protein using a
    modified version of its natural ligand, SIRPa, fused to an
    immunoglobulin Fc region. The fusion protein has similar pharmacological
    properties to a traditional monoclonal antibody and other Fc fusion
    proteins on the market and in development. However, the SIRPaFc protein
    appears to have distinct binding properties compared to those of many
    anti-CD47 monoclonal antibodies. The safety data expected in the third
    quarter, combined with a large body of existing efficacy data, will
    direct the company's selection of a definitive clinical development
    candidate. A formal IND-enabling program is expected to commence shortly
    thereafter. 
    
--  Dosing in a Phase I multicenter dose-escalation study (50mg-350mg) with
    tigecycline in patients with relapsed or refractory acute myeloid
    leukemia (AML) is also expected to be completed in the third quarter.
    The program is based on Dr. Aaron Schimmer's discovery that tigecycline,
    an FDA-approved antibiotic, selectively targets leukemia cells and
    leukemic stem cells by inhibiting mitochondrial protein synthesis and
    thus shutting down the cells energy supply. The upcoming data will guide
    the design of a Phase II trial projected to commence in 2014. In
    parallel, the company and its collaborators are actively investigating
    improved formulations and novel analogues of tigecycline, efforts which
    are central to the commercialization of this technology. 
    
--  The company is continuing its ongoing dialogues with third parties
    regarding partnerships and collaborations on several of its internal
    programs, as well as its discussions related to the in-licensing of
    additional cancer stem cell assets. SCT anticipates being in a position
    to provide more details on these efforts by year end. 
    
--  The company is in the process of ceasing all activities associated with
    its pre-merger historic regenerative neurology programs and anticipates
    completing this in the third quarter. Moving forward all resources will
    be focused on the company's promising cancer stem cell programs. While
    SCT will attempt to monetize its intellectual property underpinning the
    legacy programs, the company has determined that doing so through the
    joint venture previously contemplated is not a viable option. 
    
--  SCT has initiated several efforts to amplify and broaden its visibility
    in a cost-effective way. These range from strengthening its Board of
    Directors and developing relationships with additional key opinion
    leaders in the cancer stem cell field, to working with investor relation
    firms and capital markets advisors, such as the recently announced
    appointment of ProActive Capital Group to assist in increasing awareness
    of the company among investors.



About Stem Cell Therapeutics:

Stem Cell Therapeutics Corp. (SCT) is a biopharmaceutical company dedicated to
advancing cancer stem cell discoveries into novel and innovative cancer
therapies. Building on over half a century of leading and groundbreaking
Canadian stem cell research, the company is supported by established links to a
group of Toronto academic research institutes and cancer treatment centers,
representing one of the world's most acclaimed cancer research hubs. SCT's
clinical stage programs include the recently in-licensed program focused on the
structure of tigecycline, which is currently being evaluated in a multi-centre
Phase I study in patients with acute myeloid leukemia (AML), as well as
TTI-1612, a non-stem cell asset being tested in a 28-patient Phase I trial in
interstitial cystitis ("IC") patients, which is near completion. The Company
also has two premier preclinical programs, SIRPaFc and a CD200 monoclonal
antibody (mAb), which target two key immunoregulatory pathways that tumor cells
exploit to evade the host immune system. SIRPaFc is an antibody-like fusion
protein that blocks the activity of CD47, a molecule that is upregulated on
cancer stem cells in AML and several other tumors. The CD200 mAb is a fully
human monoclonal antibody that blocks the activity of CD200, an
immunosuppressive molecule that is overexpressed by many hematopoietic and solid
tumors. For more information, visit www.stemcellthera.com.


Caution Regarding Forward-Looking Information:

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include changing market conditions; the successful and timely completion
of pre-clinical and clinical studies; the establishment of corporate alliances;
the impact of competitive products and pricing; new product development risks;
uncertainties related to the regulatory approval process or the ability to
obtain drug product in sufficient quantity or at standards acceptable to health
regulatory authorities to complete clinical trials or to meet commercial demand;
and other risks detailed from time to time in SCT's ongoing quarterly and annual
reporting. Except as required by applicable securities laws, SCT undertakes no
obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com


Investor Contact: ProActive Capital
Jeff Ramson
(646) 863-6341
jramson@proactivecapital.com

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024